Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

124 CIDOFOVIR
Eyes
Iritis
(2006): Kottke MD+, JAmAcadDermatol55(3), 533
(1999): Neau D+, Clin Infect Dis 28(1), 156
(1999): Tseng AL+, Ann Pharmacother 33(2), 167
(1997): Davis JL+, Arch Ophthalmol 115(6), 733
(1997): Palau LA+, Clin Infect Dis 25(2), 337
(1997): Taskintuna I+, Ophthalmology 104(11), 1827 (32%)
Ocular hypotension
(2003): Hackethal U+, Klin Monatsbl Augenheilkd 220(6), 391
Retinal detachment
(2003): Hackethal U+, Klin Monatsbl Augenheilkd 220(6), 391
(1998): Akler ME+, Ophthalmology 105(4), 651 (44%)
(1997): Taskintuna I+, Ophthalmology 104(11), 1827 (6%)
Uveitis
(2006): Kottke MD+, JAmAcadDermatol55(3), 533
(2005): Cano Parra J+, Arch Soc Esp Oftalmol 80(3), 137
(2003): Hackethal U+, Klin Monatsbl Augenheilkd 220(6), 391
(2003): Tacconelli E+, Eur J Clin Microbiol Infect Dis 22(2), 114
(2001): Accorinti M+, Ocul Immunol Inflamm 9(3), 211
(2001): Chakrabarti S+, Bone Marrow Transplant 28(9), 879
(2001): Martinez de la Casa JM+, Arch Soc Esp Oftalmol
76(4), 213
(2001): Rougier MB+, JFrOphtalmol24(5), 491
(2001): Soltau JB, Ocul Immunol Inflamm 9(3), 137
(2000): AIDS 14(11), 1571
(2000): Scott RA+, Am J Ophthalmol 130(1), 126
(1999): Ambati J+, Br J Ophthalmol 83(10), 1153
(1999): Cochereau I+, Ocul Immunol Inflamm 7(3–4), 223
(1999): Plosker GL+, Drugs 58(2), 325
(1997): Chavez-de la Paz E+, Ophthalmology 104(3), 539
Vision impaired
(2003): Rapp P+, JFrOphtalmol26(7), 717
(1999): Bainbridge JW+, Eye 13 (Pt 3a), 353
(1998): Prescrire Int 7(37), 135
Vision loss
(2003): Hackethal U+, Klin Monatsbl Augenheilkd 220(6), 391
(1997): Friedberg DN, Arch Ophthalmol 115(6), 801
(1997): Taskintuna I+, Ophthalmology 104(11), 1827
Other
Application-site reactions (sic) (39%)
(1998): Sacks SL+, Antimicrob Agents Chemother 42(11), 2996
(1998): Zabawski EJ+, JAmAcadDermatol39, 741
Chills (24%)
Myalgia/Myositis/Myopathy/Myotoxicity
Nephrotoxicity
(2005): Izzedine H+, Am J Kidney Dis 45(5), 804
(2005): Ortiz A+, Antivir Ther 10(1), 185
(2002): Verhelst D+, Am J Kidney Dis 40(6), 1331
CILAZAPRIL
Trade names: Inhibase (Roche); Vascace (Roche)
Indications: Hypertension
Category: Angiotensin-converting enzyme inhibitor
Half-life: 9 hours
Clinically important, potentially hazardous interactions
with: alcohol, diuretics
Reactions
Skin
Angioedema
(1997): Schiller PI+, Allergy 52(4), 432
(1992): Szucs T+, Cardiology 80(1), 34
Edema
(1992): Szucs T+, Cardiology 80(1), 34 (facial)
Lupus erythematosus
(1995): Fernandez-Diaz ML+, Lancet 345(8946), 398
Pemphigus foliaceus
(1998): Buzon E+, Acta Derm Venereol 78(3), 227
Pemphigus vulgaris
(2005): Goldberg I+, Acta Dermatovenerol Croat 13(3), 153
(2000): Orion E+, Acta Derm Venereol 80(3), 220
Rash (sic)
(1996): Abraham G+, Orv Hetil 137(29), 1583
Other
Cough
(2007): Tumanan-Mendoza BA+, J Clin Epidemiol 60(6), 547
(2003): Buranakitjaroen P+, J Med Assoc Thai 86(7), 647
(1996): Rosenthal JR+, Cardiology 87(1), 54
(1994): Dossegger L+, J Cardiovasc Pharmacol 24(Suppl 3), S38
(1994): Karpov YA+, J Cardiovasc Pharmacol 24(Suppl 3), S86
(1993): Coulter DM, NZMedJ106(968), 497 (2.9%)
(1993): Reisin L, Cardiology 82(Suppl 2), 47
(1992): Szucs T+, Cardiology 80(1), 34
Inappropriate secretion of antidiuretic hormone (SIADH)
(2001): Arinzon ZH+, JAmGeriatrSoc49(12), 1735
CILOSTAZOL
Synonym: OPC13013
Trade name: Pletal (Pfizer)
Indications: Peripheral vascular disease, intermittent claudication
Category: Antiplatelet; Phosphodiesterase inhibitor; Vasodilator,
peripheral
Half-life: 11–13 hours
Clinically important, potentially hazardous interactions
with: clarithromycin, erythromycin, fondaparinux
Reactions
Skin
Edema (